Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19 (Co-CLARITY)
A Randomized, Open-Label, Single Center Clinical Trial to Assess the Efficacy and Safety of Convalescent Plasma to Hospitalized Adult COVID-19 Patients as Adjunctive Therapy to Reduce the Need for ICU Admission: Co-CLARITY Trial
Sponsor: University of the Philippines
Terminated
Limited enrolment (unable to achieve target sample size)
Other terminated trials from University of the Philippines
More terminations from University of the Philippines
This PHASE2/PHASE3 trial investigates Covid19 and is currently terminated or withdrawn. University of the Philippines leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
Status: Recruiting → Terminated
-
Jan 2021 — Jun 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of the Philippines
For direct contact, visit the study record on ClinicalTrials.gov .